Initial Results of Antegrade Laser Fenestrations Using Image Fusion Guidance and Company Manufactured Stent Grafts in Complex Aortic Aneurysm Repair.


Journal

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
ISSN: 1532-2165
Titre abrégé: Eur J Vasc Endovasc Surg
Pays: England
ID NLM: 9512728

Informations de publication

Date de publication:
08 2021
Historique:
received: 23 03 2020
revised: 22 01 2021
accepted: 13 03 2021
pubmed: 18 5 2021
medline: 14 8 2021
entrez: 17 5 2021
Statut: ppublish

Résumé

The aim was to describe initial outcomes of physician modified stent grafts using antegrade laser fenestrations and image fusion guidance (LEVAR) and company manufactured custom made (CM) stent grafts for the treatment of complex abdominal aortic aneurysms (CAAAs), thoraco-abdominal aortic aneurysms (TAAAs) and type I endoleaks (T1ELs). This was a retrospective single centre study. All LEVAR and Zenith (Cook) CM stent graft procedures between 1 January 2012 and 31 December 2018 were reviewed. Endpoints included intra-operative adverse events (IOAEs), in hospital mortality, re-interventions, target vessel patency, and 12 month outcomes (overall survival, freedom from re-intervention, target vessel patency). Outcomes at 12 months were estimated using the Kaplan-Meier method. A hundred patients were identified and included in the study. All patients were deemed unfit for open repair. The cohort included 22 LEVAR and 78 CM stent grafts. LEVAR cases included painful aneurysms (n = 5), > 65 mm aneurysms (n = 10), anatomical constrains and/or presence of previous renal stents (n = 7) or cases declined by the manufacturer planning centre (n = 2). IOAEs were recorded in 41% of cases (n = 9) in the LEVAR group vs. 10% (n = 8, p = .002) in the CM group. The in hospital mortality rate in the LEVAR group was 9% (n = 2) vs. 4% (n = 3, p = .30) in the CM group. The median follow up duration was 22 months (7 - 38) in the LEVAR group and 28 months (11 - 78) in the CM group. The estimate of overall survival at one year was 91% in both groups. The freedom from re-intervention rate at one year was 58% in the LEVAR group vs. 87% in the CM group. The target vessel patency rates at one year were 95% in both groups. In high risk patients deemed unfit for open repair, LEVAR may provide satisfactory 12 month overall survival and target vessel patency rates, though reported IOAE, mortality, and re-interventions rates were high thus requiring close and extensive follow up.

Identifiants

pubmed: 33994306
pii: S1078-5884(21)00267-7
doi: 10.1016/j.ejvs.2021.03.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

204-213

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

Auteurs

Jean Sénémaud (J)

Centre Hospitalier Universitaire Henri Mondor, Department of Vascular Surgery, Créteil, France.

Guillaume Fadel (G)

Centre Hospitalier Universitaire Henri Mondor, Department of Vascular Surgery, Créteil, France.

Joseph Touma (J)

Centre Hospitalier Universitaire Henri Mondor, Department of Vascular Surgery, Créteil, France.

Vania Tacher (V)

Centre Hospitalier Universitaire Henri Mondor, Medical Imaging Service, Interventional and Therapeutic Vascular and Oncologic Radiology Unit, Créteil, France.

Marek Majewski (M)

Centre Hospitalier Universitaire Henri Mondor, Department of Vascular Surgery, Créteil, France.

Frédéric Cochennec (F)

Centre Hospitalier Universitaire Henri Mondor, Department of Vascular Surgery, Créteil, France.

Hicham Kobeiter (H)

Centre Hospitalier Universitaire Henri Mondor, Medical Imaging Service, Interventional and Therapeutic Vascular and Oncologic Radiology Unit, Créteil, France.

Pascal Desgranges (P)

Centre Hospitalier Universitaire Henri Mondor, Department of Vascular Surgery, Créteil, France. Electronic address: pascal.desgranges@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH